Vivanza Biosciences Falls 5.88%: 3 Key Factors Behind the Weekly Decline
2026-10-24 17:03:38Key Events This Week 19 Oct: Stock hits 52-week low at Rs.1.41 amid sharp 17.06% drop 19 Oct: Mojo Grade upgraded from Strong Sell to Sell on technical improvement 21 Oct: Downgraded back to Strong Sell following technical deterioration 23 Oct: Week closes at Rs.1.60, down 5.88% for the week Week OpenRs.1.70 Week Close</div...
Read More
Vivanza Biosciences Ltd Falls to 52-Week Low of Rs 1.41 as Sell-Off Deepens
2026-10-19 11:41:59A sharp decline of 17.06% in a single session has dragged Vivanza Biosciences Ltd to a fresh 52-week low of Rs 1.41 on 19 Oct 2026, extending a prolonged period of underperformance against the broader market indices.
Read More
Vivanza Biosciences Ltd Upgraded to Sell on Technical Improvement Despite Lingering Fundamental Challenges
2026-10-19 08:13:29Vivanza Biosciences Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 16 Oct 2026, driven primarily by a shift in technical indicators. Despite this improvement, the pharmaceutical micro-cap continues to face significant fundamental headwinds, including operating losses and weak long-term growth prospects, which temper investor enthusiasm.
Read More
Vivanza Biosciences Downgraded to Strong Sell Amid Weak Technicals and Financial Strain
2026-10-12 08:08:38Vivanza Biosciences Ltd has been downgraded from a Sell to a Strong Sell rating as of 09 Oct 2026, reflecting deteriorating technical indicators and persistent fundamental weaknesses. Despite some positive quarterly financial results, the company’s overall outlook has worsened due to bearish technical trends, weak long-term financial strength, and consistent underperformance against market benchmarks.
Read MoreAnnouncement under Regulation 30 (LODR)-Newspaper Publication
07-Nov-2026 | Source : BSEin terms of Regulation 47 of the SEBI(LODR) Reg 2015 please find copy of the newspaper publication in the English and vernacular language of the state wherein the Unaudited Standalone and Consolidated financial Statements for the Quarter ended September 30 2026 published.
Board Meeting Outcome for Outcome Of Board Of Directors Meeting Of Vivanza Biosciences Limited Held On 06.11.2026
06-Nov-2026 | Source : BSEPursuant to Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 (Listing Regulations) we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Friday 06th November 2026 at the Registered Office of the Company has inter alia considered and approved the following businesses:
Board Meeting Intimation for Postponement And Rescheduling Of Board Meeting Pursuant To Regulation 29 & 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
03-Nov-2026 | Source : BSEVivanza Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2026 inter alia to consider and approve Unaudited Standalone and Consolidated Financial Results along with Limited Review Report of the Company for the Quarter and Half year ended September 30 2026 and Any other business with the permission of the chair
Corporate Actions
No Upcoming Board Meetings
No Dividend history available
Vivanza Biosciences Ltd has announced 1:10 stock split, ex-date: 24 Mar 23
No Bonus history available
No Rights history available